Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix - Revenue for the second quarter of 2013

Abstract:
NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.

Nanobiotix - Revenue for the second quarter of 2013

Paris, France | Posted on July 13th, 2013

Income statement



in €


Q2 2013*


H1 2013

Revenue

of which :

License

Services

48,569

45,847

2,722

95,050

93,328

2,722

*over the second quarter of 2012, the company recorded no revenue

Activity

As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.

Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).

Financial calendar

Results for the first half of 2013, on August 30, 2013

####

About Nanobiotix
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Laurent Levy
CEO
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier
Emmanuel Huynh
+33 (0)1 44 71 98 53


Yucatan
Media relations (France)
Annie-Florence Loyer
Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


College Hill
Media relations (Outside France)
Melanie Toyne Sewell
Claire Dickinson
Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

Nanobiotix revenue for Q2 2016 July 14th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project